Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 1680464, 9 pages
http://dx.doi.org/10.1155/2016/1680464
Review Article

Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer

Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, 50 Samduk-dong 2-ga, Jung-gu, Daegu 700-721, Republic of Korea

Received 24 November 2015; Accepted 13 April 2016

Academic Editor: Jie Tian

Copyright © 2016 Byeong-Cheol Ahn. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Gilham, Theranostics an Emerging Tool in Drug Discovery and Commercialisation, 2002, http://www.ddw-online.com/personalised-medicine/p148484-theranostics-an-emerging-tool-in-drug-discovery-and-commercialisation-fall-02.html.
  2. S. Jeelani, R. C. Jagat Reddy, T. Maheswaran, G. S. Asokan, A. Dany, and B. Anand, “Theranostics: a treasured tailor for tomorrow,” Journal of Pharmacy and Bioallied Sciences, vol. 6, supplement 1, pp. S6–S8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Moghimi and Z. S. Farhangrazi, “Theranostics,” in Encyclopedia of Cancer, pp. 1–3, Springer, Berlin, Germany, 2015. View at Publisher · View at Google Scholar
  4. D. Y. Lee and K. C. P. Li, “Molecular theranostics: a primer for the imaging professional,” American Journal of Roentgenology, vol. 197, no. 2, pp. 318–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. B. Silberstein, “Radioiodine: the classic theranostic agent,” Seminars in Nuclear Medicine, vol. 42, no. 3, pp. 164–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-R. Oh, B.-C. Ahn, S. Y. Jeong, S.-W. Lee, and J. Lee, “Radioiodine scan index: a simplified, quantitative treatment response parameter for metastatic thyroid carcinoma,” Nuclear Medicine and Molecular Imaging, vol. 49, no. 3, pp. 174–181, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. D.-H. Kim, J.-H. Jung, S. H. Son et al., “Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer,” Nuclear Medicine and Molecular Imaging, vol. 48, no. 1, pp. 55–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Dai, O. Levy, and N. Carrasco, “Cloning and characterization of the thyroid iodide transporter,” Nature, vol. 379, no. 6564, pp. 458–460, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. B.-C. Ahn, “Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back,” Theranostics, vol. 2, no. 4, pp. 392–402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. B. R. M. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2015. View at Publisher · View at Google Scholar
  12. E. L. Mazzaferri and S. M. Jhiang, “Differentiated thyroid cancer long-term impact of initial therapy,” Transactions of the American Clinical and Climatological Association, vol. 106, pp. 151–170, 1994. View at Google Scholar · View at Scopus
  13. E. L. Mazzaferri and S. M. Jhiang, “Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer,” The American Journal of Medicine, vol. 97, no. 5, pp. 418–428, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. E. L. Mazzaferri and R. T. Kloos, “Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1447–1463, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Luster, S. E. Clarke, M. Dietlein et al., “Guidelines for radioiodine therapy of differentiated thyroid cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 10, pp. 1941–1959, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. E. B. Silberstein, A. Alavi, H. R. Balon et al., “The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0,” Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1633–1651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Gharib, E. Papini, R. Paschke et al., “American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules,” Endocrine Practice, vol. 16, supplement 1, pp. 1–43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Tapscott, “The rectilinear scanner and an enduring legacy of education and research,” Journal of Nuclear Medicine, vol. 39, no. 5, pp. 16–33, 1998. View at Google Scholar · View at Scopus
  19. J. E. Kim, S. Kalimuthu, and B. Ahn, “In vivo cell tracking with bioluminescence imaging,” Nuclear Medicine and Molecular Imaging, vol. 49, no. 1, pp. 3–10, 2015. View at Publisher · View at Google Scholar
  20. C. M. Hong, B.-C. Ahn, S. Y. Jeong, S.-W. Lee, and J. Lee, “Distant metastatic lesions in patients with differentiated thyroid carcinoma: clinical implications of radioiodine and FDG uptake,” NuklearMedizin, vol. 52, no. 4, pp. 121–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. J. W. Lee, H. S. Min, S. M. Lee, H. W. Kwon, and J. K. Chung, “Relations between pathological markers and radioiodine scan and 18F-FDG PET/CT findings in papillary thyroid cancer patients with recurrent cervical nodal metastases,” Nuclear Medicine and Molecular Imaging, vol. 49, no. 2, pp. 127–134, 2015. View at Google Scholar
  22. B.-C. Ahn, “Applications of molecular imaging in drug discovery and development process,” Current Pharmaceutical Biotechnology, vol. 12, no. 4, pp. 459–468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Salvatori and M. Luster, “Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, pp. 821–828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. H. Son, S. Lee, J. Jung et al., “Analysis of clinical factors for the determination of optimal serum level of thyrotropin after recombinant human thyroid-stimulating hormone administration,” Nuclear Medicine and Molecular Imaging, vol. 49, no. 4, pp. 268–275, 2015. View at Publisher · View at Google Scholar
  25. C. M. Hong, W. K. Lee, S. Y. Jeong, S.-W. Lee, B.-C. Ahn, and J. Lee, “Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation,” Nuclear Medicine Communications, vol. 35, no. 11, pp. 1119–1126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Spitzweg, K. C. Bible, L. C. Hofbauer, and J. C. Morris, “Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets,” The Lancet Diabetes and Endocrinology, vol. 2, no. 10, pp. 830–842, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. W. Oh, J. C. Paeng, and J. Chung, “New strategies for combined radioiodine therapy in refractory thyroid cancer,” Journal of Korean Thyroid Association, vol. 8, no. 1, pp. 26–35, 2015. View at Publisher · View at Google Scholar
  28. S. Micali, S. Bulotta, C. Puppin et al., “Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer,” BMC Cancer, vol. 14, no. 1, article 303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Rothenberg, D. G. McFadden, E. L. Palmer, G. H. Daniels, and L. J. Wirth, “Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib,” Clinical Cancer Research, vol. 21, no. 5, pp. 1028–1035, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. T. S. Plantinga, B. Heinhuis, D. Gerrits et al., “mTOR inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, pp. E1368–E1375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. K.-P. Wong and B. H.-H. Lang, “New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review,” Journal of Thyroid Research, vol. 2012, Article ID 818204, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. S. W. Oh, S.-H. Moon, D. J. Park et al., “Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 10, pp. 1798–1805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. W. T. Shen and W.-Y. Chung, “Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-γ agonists,” Thyroid, vol. 15, no. 6, pp. 594–599, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Xing, “Molecular pathogenesis and mechanisms of thyroid cancer,” Nature Reviews Cancer, vol. 13, no. 3, pp. 184–199, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Xing, B. R. Haugen, and M. Schlumberger, “Progress in molecular-based management of differentiated thyroid cancer,” The Lancet, vol. 381, no. 9871, pp. 1058–1069, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Beyer, A. Lakshmanan, Y.-Y. Liu et al., “KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells,” Endocrinology, vol. 152, no. 3, pp. 782–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. T. D. Singh, S. Y. Jeong, S.-W. Lee et al., “Inverse agonist of estrogen-related receptor gamma enhances sodium iodide symporter function through mitogen-activated protein kinase signaling in anaplastic thyroid cancer cells,” Journal of Nuclear Medicine, vol. 56, no. 11, pp. 1690–1696, 2015. View at Publisher · View at Google Scholar
  38. S. J. Beyer, X. Zhang, R. E. Jimenez et al., “Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer,” BMC Research Notes, vol. 4, article 397, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. L. Ho, R. K. Grewal, R. Leboeuf et al., “Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer,” The New England Journal of Medicine, vol. 368, no. 7, pp. 623–632, 2013. View at Publisher · View at Google Scholar